Find a clinical trial

FindClinicalTrial

If you have questions about clinical trials or want help finding the right one for you, contact our:

Patient Engagement Center Phone: 844-552-2734

This is a preliminary search of all open and enrolling clinical trials across our regions and affiliate organizations that have sponsors' permission to publish to this website.

Please use the filtering options in the right column to refine your search. Otherwise ALL open and enrolling clinical trials will display below.

« Previous 1234 Next »
Viewing Page 1 of 4 | Showing Results 1 - 5 of 17

Randomized Study of Erlotinib or Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

This randomized phase III trial studies how well erlotinib hydrochloride compared to observation works in treating patients with stage IB-IIIA...

Alison Conlin, M.D.

The Pacific Cancer Research Consortium clinical trials are offered at multiple locations throughout Oregon, Washington, Alaska, California, and Idaho. To find a location near you, please contact the Patient Engagement Center at 844-552-2734.

Phase 2, Multi-Arm Study of Niraparib Administered Alone and in Combination with Pembrolizumab in Patients with Non-Small Cell Lung Cancer

1. Cohort 1(combination of niraparib and pembrolizumab): patients must have tumors with high PD-L1 expression (TPS ≥ 50%) per local assessment,...

Basir Haque, M.D.
  • Kadlec Clinic Hematology and Oncology
  • Kadlec Research

RSH KCHO MK-3475-522 - A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC)

Inclusion Criteria:Has newly diagnosed, locally advanced, centrally confirmed TNBC, as defined by the most recent American Society of Clinical...

Ying Zhuo, M.D.
  • Kadlec Clinic Hematology and Oncology
  • Kadlec Research

Evaluating the Efficacy and Safety of Transitioning Patients From Natalizumab to Ocrelizumab.

Inclusion Criteria:Able to understand the purpose and risk of the study and provide signed informed consent document.Must have received 12 or more...

Hui-Juan Zhang, M.D.
  • Kadlec Neuroscience Center
  • Kadlec Research
« Previous 1234 Next »
Viewing Page 1 of 4 | Showing Results 1 - 5 of 17